BioSpace News Archive

Ocugen, Inc. announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ.

Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:

Gilead Sciences, Inc. announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® for a broad range of people with HIV, including those with HIV/hepatitis B coinfection and HIV/tuberculosis coinfection.

SciSparc Ltd. announced its had been received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment.

bioAffinity Technologies, Inc. announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement at a combined purchase price of $1.5625 per common share.

IO Biotech (Nasdaq: IOBT) today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Endo International plc reported financial results for the fourth-quarter ended December 31, 2023.

Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and fourth quarter and full year 2023 financial results.

enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the presentation of positive topline efficacy data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum (AFV) Annual Meeting in Tampa, Florida.

Femasys Inc. announces the first commercial procedure using its FemaSeed intratubal insemination product.